{"nctId":"NCT00103402","briefTitle":"Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome","startDateStruct":{"date":"2005-02"},"conditions":["Prostatitis"],"count":272,"armGroups":[{"label":"Alfuzosin","type":"EXPERIMENTAL","interventionNames":["Drug: Alfuzosin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Alfuzosin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has signed and dated the appropriate Informed Consent document.\n* Participant is male.\n* Participant is at least 18 years of age.\n* Participant has had symptoms of discomfort or pain in the pelvic region for at least a six-week interval at the time of presentation.\n* Symptoms bothersome enough to prompt a physician visit have been present for two years or less.\n\nExclusion Criteria:\n\n* Participant has evidence of facultative Gram negative or enterococcus with a value of greater than or equal to 1000 colony forming units (CFU) /ml in mid-stream urine (VB2).\n* Participant has previously received alfuzosin (Uroxatral®), tamsulosin hydrochloride (Flomax®), doxazosin mesylate (Cardura®), terazosin hydrochloride (HCL) (Hytrin®), or other alpha-adrenergic receptor blockers for symptoms of CP/CPPS or within the past two years for any other reason.\n* Participant has a history of prostate, penile, testicular, bladder, or urethral cancer or has undergone pelvic radiation, systemic chemotherapy, or intravesical chemotherapy.\n* Participant has a history of moderate or severe hepatic impairment, severe renal sufficiency, severe or unstable cardiovascular (i.e. prolonged QT), respiratory, hematological, endocrinological, neurological or other somatic disorders.\n* Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture, or neurological disease or disorder affecting the bladder.\n* Participant has uninvestigated, significant hematuria.\n* Participant has undergone transurethral prostatectomy (TURP), transurethral incision of the prostate (TUIP), transurethral Incision or Resection of the Bladder Neck (TUIBN), transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), balloon dilation of the prostate, open prostatectomy or any other prostate surgery or treatment such as cryotherapy or thermal therapy.\n* Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.\n* Participant is currently taking exclusionary medications such as potent CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, or ritonavir) or erythromycin.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks","description":"For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI) total score, higher scores indicate more severe symptoms and scores range from 0 to 43. The primary outcome was a decline of at least 4 from baseline to 12 weeks","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Response Assessment (GRA)","description":"The response rate for the global response assessment was based on marked or moderate improvement at 12 weeks using a 7 point scale (marked worsening, moderate worsening, no change, slight improvement, moderate improvement, marked improvement).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"32","spread":null}]},{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"36","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Subscales of the NIH-CPSI","description":"For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI), higher scores indicate more severe symptoms (for the quality-of-life score, higher scores indicate a more negative effect). Score ranges are as follows: total score, 0 to 43; pain score, 0 to 21; urinary score, 0 to 10, quality-of-life score, 0 to 12; and average pain and urgency scores, 0 to 10.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"9.0"},{"groupId":"OG001","value":"-6.5","spread":"8.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"4.5"},{"groupId":"OG001","value":"-3.0","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"2.6"},{"groupId":"OG001","value":"-1.0","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.5"},{"groupId":"OG001","value":"-1.2","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Change in Subscales of the McGill Pain Questionnaire","description":"For the McGill Pain Questionnaire, higher scores indicate greater pain. Score ranges are as follows: total score, 0 to 45; sensory score, 0 to 33; affective score, 0 to 12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"6.4"},{"groupId":"OG001","value":"-3.1","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"5.0"},{"groupId":"OG001","value":"-2.3","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.1"},{"groupId":"OG001","value":"-0.9","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Change in Medical Outcomes Study Short Form 12","description":"For the Medical Outcomes Study Short Form Health Survey 12 (SF-12), higher scores indicate better quality of life. Score range for both the physical and mental component summaries is 0 to 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"7.4"},{"groupId":"OG001","value":"3.5","spread":"8.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"10.5"},{"groupId":"OG001","value":"1.9","spread":"10.6"}]}]}]},{"type":"SECONDARY","title":"Change in Hospital Anxiety and Depression Scale","description":"For the Hospital Anxiety and Depression Scale, higher scores indicate greater anxiety and depression; range, 0 to 42.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"5.7"},{"groupId":"OG001","value":"-1.5","spread":"5.5"}]}]}]},{"type":"SECONDARY","title":"Change in International Index of Erectile Dysfunction (IIEF)","description":"For the International Index of Erectile Function, higher scores indicate better sexual function; range, 0 to 75.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"12.7"},{"groupId":"OG001","value":"-0.2","spread":"14.7"}]}]}]},{"type":"SECONDARY","title":"Change in Male Sexual Health Questionnaire","description":"For the Male Sexual Health Questionnaire, higher scores indicate better function with respect to erection and ejaculation and greater satisfaction with sexual life; range, 0 to 40.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"4.5"},{"groupId":"OG001","value":"0.6","spread":"6.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":138},"commonTop":["Pain in any body system","Gastrointestinal events","Neurologic events","Constitutional events"]}}}